Christopher Lord
Christopher Lord
Professor of Cancer Genomics, Institute of Cancer Research, London, UK
Verified email at - Homepage
Cited by
Cited by
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer, N McCabe, CJ Lord, ANJ Tutt, DA Johnson, TB Richardson, ...
Nature 434 (7035), 917-921, 2005
DNA-repair defects and olaparib in metastatic prostate cancer
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
PARP inhibitors: Synthetic lethality in the clinic
CJ Lord, A Ashworth
Science 355 (6330), 1152-1158, 2017
The DNA damage response and cancer therapy
CJ Lord, A Ashworth
Nature 481 (7381), 287-294, 2012
Political parties in the European Union
S Hix, C Lord
St. Martin's Press, 1997
Rethinking ovarian cancer: recommendations for improving outcomes
S Vaughan, JI Coward, RC Bast Jr, A Berchuck, JS Berek, JD Brenton, ...
Nature Reviews Cancer 11 (10), 719-725, 2011
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition
N McCabe, NC Turner, CJ Lord, K Kluzek, A Białkowska, S Swift, ...
Cancer research 66 (16), 8109-8115, 2006
BRCAness revisited
CJ Lord, A Ashworth
Nature Reviews Cancer 16 (2), 110-120, 2016
Legitimacy and the European union
D Beetham, C Lord
Routledge, 2014
Resistance to therapy caused by intragenic deletion in BRCA2
SL Edwards, R Brough, CJ Lord, R Natrajan, R Vatcheva, DA Levine, ...
Nature 451 (7182), 1111-1115, 2008
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
AM Mendes‐Pereira, SA Martin, R Brough, A McCarthy, JR Taylor, JS Kim, ...
EMBO molecular medicine 1 (6‐7), 315-322, 2009
Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor–positive breast cancer
MT Herrera-Abreu, M Palafox, U Asghar, MA Rivas, RJ Cutts, ...
Cancer research 76 (8), 2301-2313, 2016
Germline mutations in RAD51D confer susceptibility to ovarian cancer
C Loveday, C Turnbull, E Ramsay, D Hughes, E Ruark, JR Frankum, ...
Nature genetics 43 (9), 879-882, 2011
The shieldin complex mediates 53BP1-dependent DNA repair
SM Noordermeer, S Adam, D Setiaputra, M Barazas, SJ Pettitt, AK Ling, ...
Nature 560 (7716), 117-121, 2018
Genetic interactions in cancer progression and treatment
A Ashworth, CJ Lord, JS Reis-Filho
Cell 145 (1), 30-38, 2011
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency
Y Shen, FL Rehman, Y Feng, J Boshuizen, I Bajrami, R Elliott, B Wang, ...
Clinical Cancer Research 19 (18), 5003-5015, 2013
A decade of clinical development of PARP inhibitors in perspective
J Mateo, CJ Lord, V Serra, A Tutt, J Balmaņa, M Castroviejo-Bermejo, ...
Annals of Oncology 30 (9), 1437-1447, 2019
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors
CJ Lord, ANJ Tutt, A Ashworth
Annual review of medicine 66, 455-470, 2015
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
CJ Lord, A Ashworth
Nature medicine 19 (11), 1381-1388, 2013
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors
KJ Dedes, D Wetterskog, AM Mendes-Pereira, R Natrajan, MB Lambros, ...
Science translational medicine 2 (53), 53ra75-53ra75, 2010
The system can't perform the operation now. Try again later.
Articles 1–20